RxDoctor Payments Data

George Sotos, MD

Hematology & Oncology · Rockville, MDNPI 1033290705

Payments from drug & device makers

$96,039in general payments, 2019–2025

Across 174 payments — averaging $551.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$86K
  • Amgen$8K
  • Novartis$241
  • Pfizer$238
  • Merck$199
  • AstraZeneca$193
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$2,04697%
  • Education$663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$96,039 in reported general payments places this provider in the 65th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$3,551,660
Medicare patients
746
Services billed
150,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TibsovoIvosidenib13$438,589
Lenalidomide35$424,807
ImbruvicaIbrutinib28$402,745
JakafiRuxolitinib Phosphate20$346,629
TagrissoOsimertinib Mesylate16$273,904
JaypircaPirtobrutinib12$269,890
BrukinsaZanubrutinib16$118,813
Imatinib Mesylate13$88,543
EliquisApixaban34$45,027
Hydroxyurea44$1,663
Cyclosporine ModifiedCyclosporine, Modified12$1,286
Gabapentin19$512
Letrozole27$427
Dexamethasone22$416
Prednisone15$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$86,221$346,62920 claims
AstraZenecaTagrisso$193$273,90416 claims
Lilly USA, LLCJaypirca$57$269,89012 claims
PfizerEliquis$238$45,02734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 242 hematology & oncology providers in Maryland.

Other hematology & oncology in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →